Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fucose (Primary)
  • Indications Congenital disorder of glycosylation type 2C
  • Focus Registrational; Therapeutic Use
  • Acronyms LADDER
  • Sponsors Avalo Therapeutics

Most Recent Events

  • 01 Nov 2024 Planned End Date changed from 30 Sep 2024 to 30 Nov 2024.
  • 01 Nov 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Nov 2024.
  • 04 Mar 2024 Planned End Date changed from 31 Dec 2023 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top